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Currently, there is limited data on the immunogenicity and efficacy of human papillomavirus vaccines in Low and
Middle income countries (LMIC). The review aims to summarize the current status from published HPV vaccine
safety, immunogenicity and efficacy studies in low and middle income countries (LMIC). Electronic databases
(PubMed/MEDLINE and HINARI) were searched for peer reviewed English language articles on HPV vaccination in
LMIC that have so far been published from 1st January 2006 up to 30th January 2015. Eligible studies were
included if they had used the bivalent (bHPV) or quadrivalent HPV (qHPV) vaccines in a LMIC and investigated
safety, immunogenicity and/or efficacy. The main findings were extracted and summarized. A total of fourteen
HPV vaccine studies assessing safety, Immunogenicity and efficacy of the bivalent or quadrivalent vaccines in LMIC
were included. There are only ten published clinical trials where a LMIC has participated. There was no published
study so far that assessed efficacy of the HPV vaccines in Sub-Saharan Africa. From these studies, vaccine induced
immune response was comparable to that from results of HICs for all age groups. Studies assessing HPV vaccine
efficacy of the bivalent or quadrivalent vaccine within LMIC were largely missing. Only three studies were found
where a LMIC was part of a multi center clinical trial. In all the studies, there were no vaccine related serious
adverse events. The findings from the only study that investigated less than three doses of the bivalent HPV-16/18
vaccine suggest that even with less than three doses, antibody levels were still comparable with older women
where efficacy has been proven. The few studies from LMIC in this review had comparable safety, Immunogenicity
and efficacy profiles like in HIC. Overall, the LMIC of Africa where immune compromising/modulating situations are
prevalent, there is need for long term immunogenicity as well as surveillance studies for long term clinical effectiveness
after two and three dose regimens.
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Globally, cervical cancer is the 3rd most common malig-
nancy among women with more than 530,000 incident
cases and over 275,000 deaths annually [1]. The greatest
burden of disease (over 85 %) occurs in the LMIC where
there is lack of or limited organized screening and treatment
programs that are present in the high income countries [2].
Human Papilloma Virus (HPV), the most common
sexually transmitted infection has been recognized as a
necessary cause of cervical cancer [3]. There are over* Correspondence: ivuds@yahoo.com
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being responsible for approximately 70 % of cervical
cancers worldwide, and types 6 and 11 for 96–100 % of
genital warts infections [4]. Besides cervical cancer,
certain HPV types are also associated with a proportion
of cancers of the anus, oropharynx, the vulva, vagina
and the penis which may too be impacted by the HPV
vaccines [5]. However, the incidence rates of these cancers
are much lower (e.g., estimated global incidence for anal
cancer is 1 per 100,000 with 27,000cases per year), [5]
than that of cervical cancer and the HPV vaccines impact
on their incidence remains to be known.
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like capsid. The bivalent (Cervarix™) that protects against
HPV 16 and 18 and the quadrivalent (Gardasil™) that
protects against HPV 6, 11, 16 & 18 have been approved
in 2007 and 2009, respectively [6, 7]. Both vaccines protect
against infections and lesions induced by the HPV vaccine
types, provided that the recipient has not been exposed to
these HPV types before vaccination. Availability of the
prophylactic human papillomavirus (HPV) vaccine is seen
as a key strategy in reducing the burden of cervical cancer
in low and middle income countries (LMIC) where this
has so far been unachievable [8].
To date, at least 110 countries have licensed the bivalent
HPV vaccine and over 120 countries have licensed the
quadrivalent vaccine [9]. However, despite the licensure,
about 51 countries worldwide have incorporated the
vaccine in their National vaccination programs and
only six countries are LMIC (85 countries comprise
LMIC as per World Bank list (July 2014) [10]. WHO
recognizes the global importance of preventing cervical
cancer and HPV-related diseases and therefore recom-
mends that HPV immunization should be part of the
national immunization programs where countries meet
certain criteria [11]. There is no doubt that in LMIC,
cervical cancer an HPV related-disease, constitutes a
public health problem. However, many LMIC have
limited resources for introducing a new vaccines especially
one like the HPV whose impact may not be seen immedi-
ately when compared to those against major childhood
diseases like the rotavirus and pneumococcal vaccines
[12]. In addition, significant financial and political
barriers still exist as well as programmatic challenges
of delivering a vaccine to adolescents in settings where
school attendance is low or irregular [9]. Despite the
challenges, about twenty six of the LMIC have completed
or are currently engaged in HPV vaccine piloting activities
in order to inform decision making for future national
rollout of these vaccines [9]. According to studies that
have assessed HPV vaccine implementation in LMIC, high
rates of acceptability and coverage have been achieved
through various delivery strategies and the lesson learned
have been documented and shared [9, 13]. The challenge
posed by financial barriers has been overcome in some of
the LMIC thorough partnerships with the manufacturers
of the vaccines and the Global Alliance for Vaccine Initiative
(GAVI), therefore, many low-income countries have
the opportunity to incorporate the HPV vaccine in their
national vaccination programs.
Even as countries continue to roll out HPV vaccination
as a primary strategy to prevent cervical cancer, it will
probably be over 20 years before the impact of the vaccine
on cervical cancer is realized. Yet in the LMIC, data on
safety, immunogenicity, efficacy and long term follow up
is still sparse [14].In this review, we summarize the current status of HPV
vaccine safety, immunogenicity and efficacy studies
available in LMIC countries and discuss the findings
in the context of ongoing advances in HPV vaccine
development. We discussed the findings and identified
gaps for future research in these countries.
Review
Methods
To review the current status of HPV vaccine safety,
Immunogenicity and efficacy studies in LMIC, electronic
databases (PubMed/ MEDLINE and HINARI) were
searched for peer reviewed English language articles
on HPV vaccination in LMIC that have so far been
published from 1st January 2006 up to 31st January
2015. Search terms included HPV vaccination and the
name of a LMIC as per World Bank list (July 2014)
[10]. Studies were eligible if they were HPV vaccine
studies in a LMIC or a LMIC was included in a multi
center study. In addition, clincalTrials.gov was searched
for unpublished HPV vaccine studies that were ongoing,
stopped or withdrawn.
The titles and abstracts of the articles were reviewed
for inclusion. Articles were included if they had used the
bivalent or quadrivalent HPV vaccine in a LMIC and
investigated safety, immunogenicity and or HPV disease
end points. Studies on HPV vaccine delivery, knowledge,
attitudes and practice around HPV vaccines, opinions
about HPV vaccines were excluded. Information was
abstracted from each article on: the first author & year
of publication, country of study, study design, study
population, vaccine type, schedule of administration,
duration of follow up, serological tests to measure the
immune response and PCR assays to detect HPV DNA.
We also abstracted information of safety-(unsolicited and
solicited symptoms), immunogenicity (antibody titers) and
efficacy (based on virological and disease end points) of the
bivalent or quadrivalent vaccines among the populations
who were studied.
Results
In total, 467 studies were found on searching the data-
bases on published studies of HPV vaccines in LMICs.
On searching the titles and abstracts, fourteen HPV
vaccine studies were indentified that reported on
immunogenicity, efficacy (both summarized in Table 1) and
safety (summarized in Table 2) of the HPV vaccines. Ten
(10) were randomized controlled clinical trials; five double
blinded, three open label with one cluster randomized, two
partially blinded. There were two sub studies (longitudinal
observational studies) nested within a phase IIIb clinical
trial, three cross sectional studies (follow up of students
in a demonstration project). The studies were conducted
in Latin America (Honduras, Colombia, Guetamala), Asia
Table 1 Summary of vaccine immunogenicity and efficacy studies conducted in low and middle income countries
Study Study population Study
vaccine
Study design Vaccination schedule Follow-up Serological assays/
HPV DNA assay
Study end points Main results
Perez et al.
(2008) [15]
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Table 1 Summary of vaccine immunogenicity and efficacy studies conducted in low and middle income countries (Continued)
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Table 2 Summary of the safety endpoint data of HPV vaccines in low and middle income countries
Study Sample Safety end point assessments Results
Perez et al. (2008)
(qHPV) [15]
Multicenter cohort vaccine
n = 3147, placebo n = 2857
Reported adverse experiences that included injection site pain,
swelling and erythema and any other systemic adverse experience
as filled out on the adverse event card.
There was no significant difference in occurrence of serious
adverse events between the two groups. However, more
adverse experiences were reported by subjects who received
quadrivalent HPV vaccine compared to those subjects who
received placebo with occurrence of injection-site adverse
experiences responsible for the increase in adverse experiences
seen in these participants.
Muñoz et al. (2009)
(qHPV) [25]
Multi-center cohort vaccine
n = 1910, placebo n = 1907
Information about adverse events was gathered from participants
by general questioning at study visits and by use of a vaccine
report card. The participants received the card at every vaccination
visit to record temperatures and local and systemic adverse events.
The proportion of participants who reported serious adverse
event on day 1–15 after any vaccination was comparable
between the two groups. Injection-site adverse events were
mainly responsible for the slight increase in adverse events
that were recorded in the vaccine group
Medina et al. (2010)
(bHPV) [16]
Multi center cohort vaccine
n = 1035, placebo n = 1032
Solicited local and general symptoms (pain, redness, swelling, fever,
headache, fatigue, gastrointestinal symptoms, arthralgia, myalgia,
rash, and urticaria) were reported for 7 days while unsolicited
symptoms were reported for 30 days. The intensity of solicited
and unsolicited symptoms was graded on a scale of 0–3. SAEs,
NOCDs, medically significant conditions (MSCs), pregnancies and
their outcomes were reported up to month 12. All solicited local
AEs were considered related to vaccination. Other AEs (solicited
general and unsolicited) were assessed for causality by investigators.
The occurrence of SAEs was similar in both groups. Between
months 7 and 12, 13 girls (1.3 %) and 10 girls (1.0 %) reported
SAEs in the HPV-16/18 vaccine and control groups, respectively.
The pattern of symptoms was similar in both groups with
respect to incidence, severity and duration. The incidence of
local and solicited symptoms did not increase with the second
and third vaccine doses.
Bhatla et al. (2010)
(bHPV) [19]
Multicenter study vaccine
n = 176, placebo n = 178
For 7 days after each dose, local symptoms (pain, redness and
swelling at the injection site) and general symptoms (fever,
headache, fatigue, gastrointestinal symptoms, arthralgia, myalgia,
rash and urticaria) were solicited and recorded on diary cards.
Each symptom was graded from 1 to 3 based on the extent of
discomfort that was reported. Investigators actively solicited for
any pregnancy information from the participants and confirmed
by urine pregnancy tests prior to each vaccine dose. Unsolicited
events were followed for 30 days after each vaccination. Serious
adverse events (SAE), any new-onset chronic disorders (NOCD
and other medically significant conditions (MSC) were followed up.
Solicited local injection site symptoms (pain, redness and
swelling) were more frequent in the Vaccine group than
the Placebo group. Solicited general symptoms (fatigue,
headache and fever) were similar in both groups. There was
no difference observed between the two groups for any
unsolicited symptoms. Six SAE were reported during the
study period, two in the Vaccine group (acute appendicitis
and lymph node tuberculosis) and four in the Placebo group
(bronchogenic cyst, cataract, a miscarriage and pneumothorax
of the left lung) with none considered related to vaccination
by the investigators. None of these SAE was fatal.
Neuzil et al. (2011)
(qHPV) [27]
Longitudinal cohort alternate
dose schedules n = 903.
Events recorded up to
30 days after last dose
Solicited adverse events (local reactions and fever) and unsolicited
adverse events were recorded. All serious adverse events occurring
up to 30 days following the last dose of vaccine were documented.
The vaccine was generally well tolerated in each dosing
schedule group. Solicited and unsolicited adverse events
following any vaccination were comparable across groups.
Pain at the injection site was the most common adverse
event in all groups with most episodes classified as mild.
No serious adverse events occurred within the 30 days of
each vaccination. Throughout the study, there were no
deaths, vaccine-related serious adverse events reported.
Salif Sow et al. (2012)
(bHPV) [14]
Randomised cohort (vaccine
n = 450/ 1298 doses, placebo
n = 226), 0–12 months period
Solicited and unsolicited local symptoms (pain or swelling at
injection site) and general symptoms (arthralgia, fatigue, fever,
gastrointestinalsymptoms, headache, myalgia, rash, or urticaria).
Grade 3 symptoms defined as swelling at the injection site >50 mm in
diameter, fever >39 °C (axillary), urticaria distributed on ≥4 body areas, as
well as other symptoms that prevented normal daily activity. Serious AEs
(SAEs), other medically significant conditions.
There were no vaccine related serious adverse events and
no participant withdrew due to an adverse event. However,
the incidence of any solicited symptom was higher for vaccine
















Table 2 Summary of the safety endpoint data of HPV vaccines in low and middle income countries (Continued)
Khatun et al. (2012)
(bHPV) [18]
Randomised cohort vaccine
n = 50, placebo n = 17
Local symptoms (pain redness and swelling at the injection site) as well
as general symptoms(fever, headache, fatigue, gastrointestinal symptoms
that included nausea, vomiting, diarrhea and/or abdominal pain, arthralgia,
myalgia, rash and urticaria) were assessed for five consecutive days after
each dose. The intensity of each symptom was graded on a non-
quantifiable scale from mild, moderate and severe based on the extent
of discomfort. Unwanted events were followed for 14 days after each
vaccination.
The vaccine was well tolerated with no reports of serious
vaccine-related adverse experiences between enrollment
and Month. Fever and injection site pain were the most







(school grade [class] 6) or
age-based (girls born in 1998;
67 schools per arm) vaccine
delivery n = 5532
Vaccinees requested their parents to call in the event of any suspected
adverse event (AE) and to go to the nearest health facility. Adverse
events were also recorded at each school visit. SAEs or AEs that
indicated potential vaccine reactions were investigated by a senior
clinician
Vaccine-related adverse events were rare. There were 11 AEs
reported with 3 SAEs not thought to be related to the vaccine.
The vaccine was generally acceptable and safe [43]
Schwarz et al. (2012)
(bHPV) [17]
Four year follow up. Total
vaccinated cohort (TVC)
n = 617
Serious adverse events, new onset chronic diseases (NOCDs), medically
significant conditions, and pregnancies were recorded in the follow-up
month 48. An event was considered a potential NOCD if there was no
record of it in the participant history. Analysis of AEs incidence rate per
100,000 subjects per year was performed.
No participants withdrew from the study because of an AE,
and there were no fatal events. There were no vaccine
related SAEs. There was no apparent difference in terms of
incidence rates of AEs between the study groups in the
cumulative follow-up time. A total of 32 pregnancies were
reported throughout the study period in HPV-16/18 vaccine
recipients with 29 participants giving birth to healthy babies.
Skinner et al. (2014)
(bHPV) [26]
Multicenter cohort vaccine
n = 2881, placebo n = 2241.
Four year follow-up.
Solicited symptoms for 7 days and unsolicited symptoms for 30 days
after each vaccination were recorded by participants. Serious adverse
events, new-onset chronic diseases, new-onset autoimmune diseases,
medically significant conditions, pregnancy, and pregnancy outcomes
were recorded throughout the 48-month follow-up.
Solicited injection-site symptoms and other general solicited
symptoms occurred more in the vaccine group than in the
control group. Overall, the incidence of unsolicited symptoms,
serious adverse events, medically significant conditions,
new-onset chronic disease, and new-onset autoimmune disease
was similar in both groups, and pregnancy outcomes did not
differ between groups. There were seventeen deaths that
occurred, 14 (<1 %) of 2881 women in the vaccine group and
three (<1 %) of 2871 in the control group. None of these deaths
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(Senegal, Tanzania and Uganda). From ClinicalTrials.gov,
a total of 159 registered ongoing or completed HPV vac-
cine clinical trials were identified out of which 18 were
from a LMIC; ten published, six ongoing or completed,
two withdrawn and another suspended.
Immunogenicity of the HPV vaccines
Perez et al. [15] in Guetemala conducted a multi center
placebo controlled clinical trial that recruited 6004 fe-
male participants within age range of 9–24 years. Partici-
pating countries included Brazil, Mexico, Colombia,
Costa Rica, Guatemala and Peru. Participants were ran-
domized into two arms; immunization with intramuscu-
lar (deltoid) injections of the quadrivalent HPV vaccine
or placebo. Procedures were carried out at enrollment
(day 1), month, 2 and month 6. In this study, the partici-
pants were stratified according to age; 9–15, 16–24. At
month 7, the 9–15 years old girls had a stronger anti-
body responses (HPV 6, 982.9 (95 % CI: 872.4−1107.5);
HPV 11, 1242.7 (95 % CI: 1094.4−1411.3); HPV 16,
5163.9 (95 % CI: 4449.8−5992.7); HPV 18, 1036.5 (95 %
CI: 890.1–1207.0) compared to those 16–24 years (HPV
6, 525.0 (95 %CI 502.6–548.4), HPV 11 730.9 (95 % CI
695.7–767.8), HPV 16 2540.3 (95 % CI: 2379.5–2711.9);
HPV 18, 473.7 (95 % CI: 448.0–500.8) [15]. The results
of the study showed that the vaccine was highly
immunogenic in these participants.
Medina et al. [16] published the initial immunogenicity
results of a phase III partially blinded, randomized, pla-
cebo controlled trial among adolescent girls (mean age
12 years) from 12 countries including Honduras (57
centers located in Australia, Colombia, the Czech
Republic, France, Germany, Honduras, Korea, Norway,
Panama, Spain, Sweden, and Taiwan). In this study, the
girls received the AS04-adjuvanted HPV-16/18 vaccine
or hepatitis A virus (the control arm) at 0, 1, and 6
months. The vaccine was immunogenic (GMT HPV16,
14,778.0 (95 % CI: 12,668.5–17,238.70) and HPV- 18,
6149.1 (95 % CI 5314.5–7114.7) enzyme-linked im-
munosorbent assay units (EU/mL) in initially seronega-
tive girls from Honduras [16]. Later, Schwarz et al. [17]
published follow-up data on the long-term immunogen-
icity of the vaccine among 10–14 years adolescent girls
in the same cohort at month 48. All participants
remained seropositive for anti-HPV-16 and anti-HPV-18
at month 48. It was observed that antibodies peaked at
month 7 and then gradually declined into a plateau from
month 18 to 24 onwards (GMTs at month 48; HPV–16,
2374.9 (95 % CI: 2205.7–2557.0) EL.U/mL and HPV- 18,
864.8 (95 % CI: 796.9–938.4) EL.U/mL) [17].
Schwarz et al. [18] followed up the same cohort of girls
who participated in the study above (Schwarz et al. [17])
and found that up to 72 months, the vaccine inducedanti-HPV-16 and −18 antibody levels remained high
(GMTs HPV-16, 1962.0 EU/mL (95 % CI 1811.3–2125.3)
and HPV-18, 749.6 EU/mL (95 % CI: 687.7–817.0) [18].
Anti-HPV-16 and −18 antibody GMTs at month 72 in
this study were 65.8- and 33.0-fold higher than those
induced by natural infection, respectively [18]. Further,
based on a statistical model, it was predicted that the
antibodies may remain above those induced by natural
infection for over 20 years [17].
Similar immunogenicity results were realized from a
randomized controlled trial using the bivalent HPV-16/
18 vaccine among healthy Bangladesh girls 9–13 years
(n = 67) by Khatun et al. [18]. The participants were
followed up to 7 months from 1st vaccine dose. In this
study, a commercial ELISA kit detecting HPV IgG anti-
bodies to HPV-16/18 was used to detect seropositivity to
HPV-16/18 with a cut-off value of 450 nm calculated
from the mean optical density (OD) of the negative
control [18]. Notwithstanding a small sample size, and a
different HPV antibody assay, the sero-conversion rate
was 97.5 % [18] as opposed to 100 % in the previous
study of Schwarz et al. [17].
Bhatla et al. [19] assessed the immunogenicity of the
bivalent vaccine among healthy Indian women of an
older age group 18–35 years (n = 330) up to month 7.
They also found the vaccine to be highly immunogenic
in this older population of women (Fig. 1) [19].
In the LMIC of Africa, studies that addressed im-
munogenicity with the three dose bivalent HPV-16/18
vaccine were conducted in Tanzania, Senegal and
Uganda. Sow et al. [14] published results from a multi-
center placebo-controlled trial in Tanzania and Senegal
among girls (age 10–14; 15–25 years) (n = 676). Girls
were randomized to receive HPV-16/18 AS04-adjuvanted
vaccine (n = 450) or placebo (n = 226) at 0, 1, and 6
months and followed up to 12 months post 1st vaccine
dose. Similar to the studies above, girls < 15 years had a
higher immune response than girls aged ≥15 years at
month 7 month [14]. In this study, the HPV-16/18 AS04-
adjuvanted vaccine was highly immunogenic and safe
among HIV–seronegative African girls and young women
(Fig. 1) [14].
In the same cohort, Brown et al. [20] conducted a sub-
cohort study among the Tanzanian girls (n = 298) to
measure the impact of malaria infections and helminth
infestation on the immunogenicity of the bivalent HPV-
16/18 vaccine. They found that parasitic infestations
were common and that there was no evidence of a
reduction in HPV-16 or HPV-18 GMT at Month 7 or at
month 12 follow-up visits among participants with
helminths or malaria [20]. However, it was observed that
participants with malaria had increased GMTs though
the mechanism and significance for the increase in
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Fig. 1 a & b Showing comparable Geometric mean titers for anti–HPV-16/18 at month 7 in 3 immunogenicity studies Africa [14], India [20] and
Europe [24] across the age strata. In the vaccine groups for all the three studies, seropositivity to anti-HPV-16/18 was 100 % in initially
seronegative participants
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tive cross sectional study at month 18 month of vaccin-
ation among 10–16 year old Ugandan students (n = 211)
who had been vaccinated with the bivalent HPV vaccine
in a demonstration project. At this time point, the
AS04-Adjuvanted HPV-16/18 vaccinated girls showed a
higher level of antibodies to HPV-16/18 than those who
were not vaccinated [22]. Among the same cohort of
students a follow-up to month 24 visit was done to as-
sess the effect of helminth and malaria exposure on the
immune response. They found no reduction in HPV-16
or HPV-18 antibodies among girls who had evidence of
helminth or malaria exposure (Nakalembe et al. [23]),
which was similar to the Tanzanian studies. However, in
the Ugandan study, malaria exposure was measured as
opposed to active infection in the Tanzanian study [23].
Immunogenicity data based on 7 months geometric
mean titers to Anti-HPV-16/18 was compared between
studies that were purely in a LMIC (Africa [14] and
India [19]) as well Europe [24] (Fig. 1). The results arecomparable across the different populations in these
studies (Fig. 1).
In conclusion, all together, the studies that have been
conducted so far within diverse populations of the
LMIC have demonstrated strong immunogenicity of
the prophylactic HPV vaccines among girls, young and
old women.
Studies that assessed virological and disease end points
Three trials that assessed vaccine efficacy against viro-
logical and disease end point in addition to safety and
immunogenicity were found where a LMIC had partici-
pated. The Philippines and Guetamala were the only
LMICs that participated in these studies. Perez et al. [15]
(Guetamala) in the trial described for immunogenicity
above, carried out analyses of the quadrivalent vaccine
efficacy in the per protocol efficacy population (PPE).
This population included all subjects aged 16–24,
received all three vaccine doses and were seronegative as
well as PCR-negative for the relevant HPV type(s) at
Nakalembe et al. Infectious Agents and Cancer  (2015) 10:17 Page 10 of 14enrollment and PCR-negative at month 7 to the vaccine-
related HPV types. They concluded that among vacci-
nated subjects in the per-protocol population from Latin
America, the quadrivalent HPV vaccine was 92.8 and
100 % effective in preventing CIN and external genital
lesions related to vaccine HPV types, respectively [15].
Muñoz et al. [25] conducted a multicentre, parallel, ran-
domized, placebo-controlled, double-blind study among
24–45 years old women from seven countries including
the Phillipines, the only LMIC in the group(n = 3819; 38
study centers in Colombia, France, Germany, Philippines,
Spain, Thailand, and the USA). Women were randomized
to receive placebo (n = 1911) or the quadrivalent HPV
vaccine (n = 1908) in order to assess the safety,
immunogenicity and efficacy of the quadrivalent HPV
vaccine. HPV-6/11/16/18 related incidence of infec-
tion of at least 6 months’ duration and cervical and
external genital disease (including cervical, vulvar, or
vaginal intraepithelial neoplasia; adenocarcinoma in
situ; cervical, vulvar, or vaginal cancer; and genital
warts) were measured for efficacy. In the per-protocol
population (no infection at baseline) efficacy against
disease or infection related to HPV-6/11/16 and 18
was 90.5 % (95 % CI: 73.7–97.5) (4 of 1615 cases in
the vaccine group versus 41/1607 in the placebo
group) and 83 · 1 % (95 %CI: 50.6–95.8) (four of 1601
cases versus 23/1579 cases) against disease or infection
related to HPV 16 and 18 alone. In the intention-to-treat
population (infection present at baseline) efficacy against
HPV-6/11/16/and 18 endpoint was 30 · 9 % (95 % CI:
11.1–46.5) (108/1886 cases versus 154/1883 cases) and
against HPV-16/18 was 22 · 6 % (95 %CI 2 · 9−41 · 9) (90/
1886 cases versus 115/1883 cases), since infection and
disease were present at baseline [25]. In this study, Muñoz
et al. found that the quadrivalent HPV vaccine was effica-
cious in women aged 24–45 years who were not infected
with vaccine HPV types at enrolment.
Currently, there is an on-going phase 3, multinational,
double-blind, and randomized controlled trial with the
bivalent vaccine, involving 13 countries, with the
Philippines as the only participating LMIC (Australia,
Canada, Mexico, the Netherlands, Peru, Philippines,
Portugal, Russia, Singapore, Thailand, the UK, and the
USA) named Vaccine Immunogenicity and Efficacy
study (VIVIANE) Skinner et al. [26]. The main objective
of the VIVIANE trial is to assess immunogenicity, effi-
cacy and safety of the HPV 16/18 AS04-adjuvanted
vaccine among women 26 years or older [26]. Interim
results at mean follow up of 40.3 months are similar to
Muñoz et al. 2009 study and have shown that the HPV
16/18 vaccine is efficacious against infections and
cervical abnormalities associated with the vaccine types,
as well as infections with the non-vaccine HPV types 31
and 45 [26] among women ≥ 26 years.Individual country analysis of efficacy end points in
these studies was not done most probably due to inad-
equate sample size. Therefore, conclusions of efficacy
end points from participating countries individually may
not be drawn.
Safety of the HPV vaccines
Safety of the HPV vaccines was also assessed in most of
the studies described above (summarized Table 2). In
most of these studies, assessments for safety were based
on both solicited and unsolicited local symptoms like
pain and swelling at injection site as well systemic symp-
toms like arthralgia, fatigue, fever, gastrointestinal symp-
toms, headache, myalgia, rash, or urticaria (Table 2).
In some of the studies, new onset of chronic dis-
eases (NOCDs), medically significant conditions (MSCs),
pregnancies and their outcomes were also assessed
[14, 16, 17, 20]. In all these studies (Table 2), the HPV
vaccines were found to be generally safe and well
tolerated among the participants. Injection site pain
was the most common complaint which appeared
more frequently among the vaccine recipients in most
of the studies while in others there was no apparent
difference in the incidence of AEs between the vaccine
and non vaccine groups (Table 2). In all the studies,
there were no vaccine related serious adverse events
(Table 2).
Alternate dose schedules
Neuzil et al. [27] in Vietnam conducted an Open-label,
cluster randomized, non-inferiority study assessing four
schedules of the quadrivalent HPV vaccine delivered in
21 schools to 903 adolescent girls (aged 11–13 years at
enrollment) to determine the immunogenicity of differ-
ent dosing schedules of quadrivalent HPV vaccine. The
schedules were the standard dosing schedule (at 0, 2,
and 6 months) and three alternative dosing schedules (at
0, 3, and 9 months; at 0, 6, and 12 months; or at 0, 12,
and 24 months. They found that among this population
of adolescent girls in Vietnam, administration of the
quadrivalent HPV vaccine on standard and alternative
schedules was immunogenic and well tolerated. The use
of two alternative dosing schedules (at 0, 3, and 9 months
and at 0, 6, and 12 months) compared with a standard
schedule (at 0, 2, and 6 months) did not result in inferior
antibody concentrations [27]. Pre-specified non-inferiority
was not met for the alternative dose schedule group
receiving doses at 0, 12, and 24 months. In the same
cohort of girls, LaMontagne et al. [28] conducted a follow
up study and reported results at 29–32 months after the
third dose to investigate whether the immune responses
using three alternative dosing schedules (0, 3, 9 months; 0,
6, 12 months; or 0, 12, 24 months) were non-inferior to
the standard schedule at >2 years after vaccination.
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tions at ≥29 months after three doses of HPV vaccine
regardless of dose-timing, and that extended schedules
did not produce inferior immune responses [28]. The
findings also suggested that two doses of HPV vaccine
delivered at 0 and 12 months might afford similar
protection.
In Uganda, LaMontagne et al. [29] investigated the
immunogenicity of bivalent HPV vaccines among ado-
lescent girls at mean age of 10 years who received one,
two, or three vaccine doses in a demonstration project.
They measured HPV16- and HPV18-specific anti-
bodies at ≥24 months after the last vaccine dose using
an enzyme linked immunoassay in girls who received
one (n = 36), two (n = 145), or three (n = 195) doses.
They found that even though immunogenicity with less
than three doses did not meet a priori non-inferiority
thresholds, antibody levels measured at ≥24 months
after last dose were similar to those of adult women
who had been followed for more than eight years for
efficacy [29].
In conclusion, alternative dose schedules have shown
non inferior immunogenicity among the 10–13 year old
age group when compared to standard dosing schedules
in populations where they have been evaluated.
Unpublished, ongoing and stopped HPV vaccine studies
in LMICs
In addition to the published clinical trials from LMICs
in this review, a total of ten unpublished ongoing, sus-
pended, withdrawn or completed clinical trials were
found (clinicalTials.gov; accessed 4th May 2015) within
LMIC. India had the largest number (8/10) with six of
them using qHPV while two were using bHPV. The
qHPV Indian trials are mainly safety and immunogen-
icity studies among HIV populations (two of them),
healthy populations (two of them; one suspended) while
another was a vaccine delivery strategy study which was
withdrawn. Likewise, the two bHPV vaccine studies are
assessing safety and Immunogenicity among HIV posi-
tive and negative populations (clinicalTrials.gov accessed
4th May 2015).
However, in India, there were media allegations that
HPV vaccines caused death of four girls in Northern
India. Acting on this information, the government of
India suspended two HPV vaccine studies and instituted
an inquiry into the safety of both vaccines [30]. One
study was a clinical trial to investigate the immunogenic
efficacy of two doses (6 months apart) compared with
the three doses (0, 2, 6 months) of Gardasil while the
second one was a feasibility study to assess a school-
based and community-based vaccination program [30].
The inquiry concluded that no deaths were related to
the vaccine [31].In addition to the Indian studies, two safety and im-
munogenicity studies were found among pre adolescents
in Kenya; HIV positive and negative populations (clini-
calTrials.gov accessed 04th May 2015). Results from
these trails are yet to be published.
Discussion
We have reviewed results of safety, immunogenicity,
efficacy (virological and disease end points) for both the
bivalent and quadrivalent HPV vaccine in LMIC. This
review identified ten published clinical trials that involved
a LMIC. According to the clinicalTrials.gov (accessed
23rd March 2015), a total of 159 cervarix or gardasil clin-
ical trials have so far been registered, ongoing or com-
pleted. Both the published and unpublished clinical trials
within the LMICs trials are still few when compared to
the HICs. The discrepancy may in part be due to ethical,
scientific and logistical challenges that face the conduct of
clinical research in LMIC [32].
In this review, we found that only five HPV vaccine
studies (one clinical trial; two longitudinal observational
studies nested within the clinical trial; two cross sec-
tional studies) have been conducted within the LMICs of
Sub-Saharan Africa (SSA), yet, SSA has a high burden of
cervical cancer. Additionally, SSA is one of the countries
with a high incidence of penile cancers, though overall,
its global incidence is low [4]. SSA has prevalent poten-
tially immune modulating situations (Malaria, Helminths,
HIV and malnutrition) that may affect the immune
response and finally efficacy of the HPV vaccines [6].
However, the few studies so far have demonstrate that the
HPV vaccines are highly immunogenic and safe, though
there is need for population based studies designed to
address long term effectiveness of the HPV vaccines based
on the virological and disease end points.
All the studies in this review that investigated immedi-
ate vaccine safety did not record a serious adverse event
related to the vaccine. Serious adverse events that have
been reported as potential signals have not been con-
firmed after detailed investigations [33]. The safety
results from these studies are similar to what has been
concluded from reviews of long term safety that
included studies from HICs [34]. However, much as the
safety reports are so far reassuring, as with any new
vaccine, post marketing surveillance mechanisms should
be in place to monitor long-term safety [35].
Published vaccine efficacy studies that were found in
this review where a LMIC participated were multi center
studies. Currently, we identified only six clinical trials
with cervarix or gardasil that are ongoing or completed
within a LMIC (ClinicalTrials.gov accessed 23rd March
2015). Notably in Sub-Saharan Africa, two Phase three
randomized clinical trials that were found (clinical
Trials.gov accessed 23rd March 2014) are all from
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qHPV vaccine among HIV-infected adolescents (9–14)
while one of them is assessing safety, tolerability and
immunogenicity of the qHPV vaccine among healthy
women 9–26 years. The other four ongoing or com-
pleted trials with cervarix or gardasil are also assessing
safety and immunogenicity among healthy and HIV
infected Indian populations as well as alternative dose
regimens. Results from these trials which are yet to be
posted will not feature vaccine efficacy as this was not
part of the objectives. Therefore, HPV vaccines efficacy
studies within the LMICs should be considered.
The few clinical trials that were conducted within the
LMIC demonstrated that the 9–15 year old age group
mounted a higher immune response when compared to
the older age groups (above 15 years). This finding was
consistent with what was observed in other clinical trials
that were conducted elsewhere [36]. Further, efficacy
among LMIC adult women (>25 years) populations was
demonstrated as well as cross protective potential as has
been observed in other studies [7].
After evidence of non-inferiority of two-dose schedule
when compared to the three-dose schedule from clinical
trials, WHO currently recommends a two dose schedule
at 6-months interval of the bivalent or quadrivalent
vaccine for girls vaccinated before age 15 years and a
three dose schedule for those aged ≥15 years or those
with immune compromising conditions [33]. On alterna-
tive dose regimens, the only published clinical trial in
this review assessed different schedules of the three
doses instead of two doses [27]. For LMIC, it is more
important to have studies that assess less dose regimens
instead of alternative three dose schedules as it is of crit-
ical importance to save resources on any extra dose
administered. The only published study that investigated
less than three doses of the bivalent HPV-16/18 vaccine
was not a randomized controlled trial of 2 versus three
dose regimen and had a small sample size and therefore
was not powered to test the primary hypothesis of non-
inferiority. Nevertheless, this study still suggests that
even with less than three doses, antibody levels were still
comparable with older women were efficacy has been
proven [29]. However, it remains to be known for how
long the level of response from the two doses would last.
Second generation vaccines are being considered to
address some of the limitations faced by LMIC with the
current prophylactic vaccines, which include limited
valence and dependency on the cold chain among others
[7]. So far, Merck Inc. has developed a nine valent HPV
vaccine, which target five additional oncogenic HPV
types 31, 33, 45, 52 and 58 to 6, 11, 16 and 18. This
vaccine has been approved and registered by the FDA
for use in girls and young women 9 to 26 years of age
for the prevention HPV 16, 18, 31, 33, 45, 52 and 58related cervical, vulvar, vaginal, and anal cancers as well
as genital warts caused by HPV types 6 and 11 [37].
Worldwide, HPV-16/18 contribute to about 70 % of cer-
vical cancer cases while HPV-31/33/45/52/58 a further
20 % [38]. Therefore, this vaccine has the potential to
prevent 90 % of cervical cancer disease worldwide since
the estimates of the 9-HPV types in cervical cancer do
not significantly differ across the world [39]. However, a
review on Human papillomavirus distribution in invasive
cervical carcinoma in sub-Saharan Africa found that the
relative contribution of HPV-45 to ICC was significantly
higher in SSA when compared to the rest of the world
[40]. In this study, it was also found that HPV18 was
higher and HPV45 lower in HIV endemic areas. How-
ever, the significance of this finding remains to be under-
stood in light of emerging evidence that HPV vaccines
are immunogenic even in HIV infected individuals
despite need for more long term data [41]. Further,
Ndiaye et al. highlighted the importance of HPV-45 as
an important candidate for future vaccines, despite the
fact that varying degrees of cross protection against
HPV45 have been described for the current bivalent and
quadrivalent vaccines [38]. Since the level of potential
benefit of the nine-valent vaccine may be attenuated by
the cross protection properties of the previous vaccines,
the benefits must be weighed against the cost of the
vaccines [42] especially in LMIC. However with no
ongoing studies to assess the current vaccines impact
over time, it will be difficult to analyse the cost effective-
ness of the second generation vaccines in the LMIC. In
addition, decisions to revaccinate with the new HPV
vaccines those who are already vaccinated with the older
vaccines will be difficult without this evidence.
Conclusion
The few studies in this review that assessed safety,
Immunogenicity and efficacy of the HPV vaccines in the
LMIC had a similar safety and Immunogenicity profile
like in high income countries. Compared to high income
countries, there are much fewer studies on safety and
immunogenicity conducted in LMIC and the number of
study participants is also lower, so data from LMIC is
still limited. Notably, HPV vaccine efficacy data is largely
lacking with no efficacy study specifically identified for a
LMIC though the available studies have provided evidence
of efficacy. Specifically, in Sub-Saharan Africa where
immune compromising/modulating situations are preva-
lent there is need for more robust better designed long
term immunogenicity and effectiveness studies [6, 43].
Overall, there is need for evidence of the long term
clinical effectiveness and duration of protection after
two dose regimens as is elsewhere [35]. This evidence
will also help to guide decisions on the second gener-
ation vaccines.
Nakalembe et al. Infectious Agents and Cancer  (2015) 10:17 Page 13 of 14The review highlighted the HPV vaccine published
trials within the LMIC. The identified research needs are
in line with WHO recommendations for future research
needs.
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